CORC

在结果中检索

CORC

浏览/检索结果: 共94条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Design and expected performances of the large acceptance calorimeter for the HERD space mission 会议论文
Virtual, Berlin, Germany, 2021-07-12
作者:  Pacini, Lorenzo;  Adriani, Oscar;  Bai, Yong-Lin;  Bao, Tian-Wei;  Berti, Eugenio
收藏  |  浏览/下载：35/0  |  提交时间：2022/12/30
Status of the follow-up X-ray telescope onboard the Einstein probe satellite 会议论文
Virtual, Online, CA, United states, 2020-12-14
作者:  Chen, Yong;  Cui, WeiWei;  Han, DaWei;  Wang, Juan;  Yang, YangJi
收藏  |  浏览/下载：33/0  |  提交时间：2021/02/05
Complex ATP7B mutation patterns in Wilson disease and a evaluation of a yeast model for functional analysis of the individual variant 会议论文
作者:  Chen, Yongpeng;  Li, Xiaojin;  Zhang, Wei;  Zhou, Donghu;  Lv, Tingxia
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
Prognosis assessment of acute-on-chronic liver failure in patients with hepatitis B virus-related cirrhosis requires specific criteria 会议论文
作者:  Gu Wenyi;  Deng, Guohong;  Zheng, Xin;  Chen, Jinjun;  Wang, Xian-bo
收藏  |  浏览/下载：88/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
Mobile agent-based mobile intelligent business security transaction model 会议论文
作者:  Jiang, Wei-Jin;  Chen, Jia-Hui;  Xu, Yu-Hui;  Wang, Yang
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace